Cancer screening co BioView sells to Massachusetts hospital

Shares in BioView have risen 447% so far in 2009.

Cancer screening technology developer BioView Ltd. (TASE:BIOV) said today that it had completed the sale of another scanning system, including specially developed algorithms, to Massachusetts General Hospital, which is using the technology as part of its circulating tumor cells (CTC) diagnostic system research.

In May, Massachusetts General Hospital (MGH) reported that its oncology unit received a $15 million research grant to help advance research into its CTC-chip system. The CTC-chip tests blood samples for cancer cells. Circulating tumor cells, which can be related to several types of cancer, travel in patients' bloodstreams and can develop tumors where the cells latch on. The cells can be very uncommon. The CTC-chip can identify a single cancer cell, even among a billion normal cells.

According to MGH, the CTC-chip, which uses advanced microfluidic technology, could be a revolutionary development in the way oncologists diagnose and treat cancer in the future.

BioView expects to continue to work with MGH on the CTC-chip system. According to BioView, its technology is an integral part of the research, and so if the research succeeds it will positively impact the company's future sales.

Shares in BioView rose over 5% today, and traded at NIS 1.46 by late afternoon. Its shares have risen over 447% in 2009, and its market cap is NIS 16.8 million.

Published by Globes [online], Israel business news - - on October 19, 2009

© Copyright of Globes Publisher Itonut (1983) Ltd. 2009

Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2018